Command Palette

Search for a command to run...

Clinical Trials · NCT03928379

A Study of LY3305677 in Participants With Type 2 Diabetes

CompletedPhase 1Mazdutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
24
Start date
Oct 2019
Locations
1 site, Germany
Primary endpoint
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
View Mazdutide compound reference